Arjen Lemmen serves as Executive Vice President of Corporate Development & Strategy at argenx, which he joined in 2016. In his role, he has successfully executed several transactions including a number of programs within the Immunology Innovation Program and the strategic collaboration with Janssen for cusatuzumab. 

Prior to joining argenx, Arjen served as a corporate finance specialist at Kempen & Co focusing on M&A, Equity Capital Markets and strategic advisory transactions in the European life sciences industry. He holds a B.Sc. in Life Science & Technology from the University of Groningen and a Master of Engineering Management from Duke University.